A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • Events
  • Expert meeting: Foundation Team in Geneva for 72nd WHO World...
Expert meeting - Event date: 20 May 2019

Foundation Team in Geneva for 72nd WHO World Health Assembly

The WHO’s annual World Health Assembly (WHA) determines the top priorities for the global health agenda. The Access to Medicine Foundation team will be in Geneva for the 72nd WHO World Health Assembly, taking place 20-28 May.

The meeting comes a week after the publication by the Foundation of the first ten-year analysis of how the pharmaceutical industry has performed on global health goals in the past decade. The report provides a springboard for discussions on how improvements can be sustained and expanded by the pharmaceutical industry in order to achieve SDG 3 on health and wellbeing by 2030. 

Since the previous World Health Assembly, the Foundation has published the first Antimicrobial Resistance Benchmark and the 6th Access to Medicine Index, both tools for guiding the pharmaceutical industry on doing more for people who live in low- and middle-income countries. The Foundation has also helped push fragile antibiotic supply up the agenda through the publication of its white paper on antibiotic shortages and antimicrobial resistance.

While in Geneva, the Foundation’s Executive Director, Jayasree K. Iyer, the Director of Strategy, Damiano de Felice, and Marijn Verhoef, Industry Lead, will participate in a series of meetings and side-events while the World Health Assembly is in progress. Specific speaking events include:

  • Profiting from profit: aligning private sector interests with UHC goals on Tuesday, May 21 at 6:00 PM to 8:00 PM (CEST). The event will focus on bringing together multi-stakeholder views on how the private sector can contribute to universal health coverage (UHC), and discuss the way forward for private sector engagement. Damiano de Felice will present at the event in collaboration with the World Health Organization.
  • GSK side event “The Steps Beyond the Science - Challenges in bringing global health products to market in a sustainable way” on Thursday, 23rd May at 12.00 pm to 2.00 pm (CEST). The event will aim to highlight and discuss the perspectives of different stakeholders on what it takes to enable sustainable and timely routes to market for global health products. Damiano de Felice will present at the event alongside PATH, Gavi, Novartis and Save the Children UK.

Will you also be at the 72nd WHO World Health Assembly? If you wish to engage with a member of the Foundation’s team on global health priorities, please contact mdeen@accesstomedicinefoundation.org.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |